ArticleJournal of Korean medical science2013
Clinical usefulness of plasma chromogranin a in pancreatic neuroendocrine neoplasm.
Article in Journal of Korean medical science, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 41 citations in OpenAlex.
- Article
- Prognostic value of clinical parameters and exosomal lncRNA NEAT1_1 in MEN1-related non-functioning pancreatic neuroendocrine tumors.Journal of neuroendocrinology · 2025Article
- Electrochemical Signal-Off Competitive Immunoassay of Chromogranin A toward a Sandwiched Graphene Oxide Structure for Neuroendocrine Tumor Detection.ACS measurement science au · 2025Article
- Role of Selected Circulating Tumor Biomarkers in Patients with Skeletal Metastatic Pancreatic Neuroendocrine Neoplasms.Journal of clinical medicine · 2023Article
- Risk Stratification of Pancreatic Neuroendocrine Neoplasms Based on Clinical, Pathological, and Molecular Characteristics.Journal of clinical medicine · 2022Review
- [Modern molecular and imaging diagnostics in pancreatic neuroendocrine neoplasms].Chirurgie (Heidelberg, Germany) · 2022Review
- RETRACTED: Synthetic Makaluvamine Analogs Decrease c-Kit Expression and Are Cytotoxic to Neuroendocrine Tumor Cells.Molecules (Basel, Switzerland) · 2020Article
- Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2019Article
- Association between genetic polymorphisms in long non-coding RNAs and pancreatic cancer risk.Cancer biomarkers : section A of Disease markers · 2019Article
- Low accuracy of chromogranin A for diagnosing early-stage pancreatic neuroendocrine tumors.Oncology letters · 2018Article
- Combined test of serum CgA and NSE improved the power of prognosis prediction of NF-pNETs.Endocrine connections · 2018Article
- Diagnosis of Pancreatic Neuroendocrine Tumors.Clinical endoscopy · 2017Review
- Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan.Journal of gastroenterology · 2017Review
- Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients.Clinical endocrinology · 2016Article
- Safety and Efficacy of EUS-Guided Ethanol Ablation for Treating Small Solid Pancreatic Neoplasm.Medicine · 2016Article
- Pancreatic Neuroendocrine Tumors: an Update.The Indian journal of surgery · 2015Article
- Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors.Cancer science · 2014Article
- Update on pancreatic neuroendocrine tumors.Gland surgery · 2014Review
- Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas.BMC endocrine disorders · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chromogranin A (CgA) is widely used as an immunohistochemical marker of neuroendocrine neoplasms and has been measurable in plasma of patients. We assessed the clinical role of plasma CgA in diagnosing pancreatic neuroendocrine neoplasm (PNEN). CgA was checked in 44 patients with pancreatic mass who underwent surgical resection from 2009 through 2011. The cutoff value for diagnosing PNEN and the relationships between CgA and clinicopathologic variables were analyzed. Twenty-six patients were PNENs and 18 patients were other pancreatic disorders. ROC analysis showed a cutoff of 60.7 ng/mL with 77% sensitivity and 56% specificity, and the area under the curve (AUC) was 0.679. Among PNEN group, the sensitivity and specificity of diagnosing metastasis were 100% and 90% respectively when CgA cutoff was 156.5 ng/mL. The AUC was 0.958. High Ki-67 index (160.8 vs 62.1 ng/mL, P = 0.001) and mitotic count (173.5 vs 74.6 ng/mL, P = 0.044) were significantly correlated with plasma CgA, but the tumor size was not. In conclusion, CgA has a little value in diagnosing PNEN. However, the high level of CgA (more than 156.5 ng/mL) can predict the metastasis. Also, plasma CgA level correlates with Ki-67 index and mitotic count which represents prognosis of PNENs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.